Can you take Nubeqa with Repotrectinib?
1 drug interaction and 10 additional warnings found for the following 2 drugs:
- Nubeqa (darolutamide)
- repotrectinib
Drug interactions
Moderate drug interactions
Moderate:
darolutamide repotrectinib
Applies to: Nubeqa (darolutamide) and repotrectinib
Repotrectinib may reduce the blood levels of darolutamide, which may make the medication less effective in some cases.
Using repotrectinib with darolutamide may also increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.
You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. Contact your doctor if your symptoms worsen or your condition changes.
Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
repotrectinib Food/Lifestyle
Applies to: repotrectinib
Consumption of grapefruit, grapefruit juice, supplements that contain grapefruit, and Seville oranges should be avoided during treatment with repotrectinib as they may increase the blood levels of repotrectinib.
This may increase the risk and/or severity of side effects such as:
- dizziness
- tiredness
- muscle pain
- nausea
- change in your sense of taste
- feeling numbness or tingling in your arms or legs
- constipation
- trouble with balance
- shortness of breath
- problems with thinking such as forgetfulness or confusion and hallucinations
- as well as more serious side effects such as severe or life-threatening inflammation of the lungs and liver injury
Talk to your doctor if you have any questions or concerns. Your doctor may be able to provide alternatives that do not interact.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Moderate food/lifestyle interactions
Moderate:
darolutamide Food/Lifestyle
Applies to: Nubeqa (darolutamide)
Food helps with the absorption of darolutamide into the blood stream.
You should take this medication with food as directed.
Disease interactions
8 potential interactions Applies to: 6 conditions, including Asthma, COPD, Liver Disease, Interstitial Lung Disease, and Neurological Disorders.
Asthma
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Asthma.
Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.
COPD
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with COPD.
Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.
Interstitial Lung Disease
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Interstitial Lung Disease.
Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.
Liver Disease
Moderate:
Nubeqa
The darolutamide in Nubeqa has a moderate potential interaction with Liver Disease.
Patients with moderate hepatic impairment (Child-Pugh Class B) have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose). No dose reduction is needed for patients with mild hepatic impairment. The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown.
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Liver Disease.
Repotrectinib can cause hepatotoxicity; this may be considered in patients with liver problems. The effect of moderate or severe liver dysfunction (total bilirubin greater than 1.5 times the upper limit of normal and any AST) on repotrectinib pharmacokinetics is unknown. The recommended dosage of repotrectinib has not been established in patients with moderate or severe liver dysfunction.
Neurological Disorders
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Neurological Disorders.
Repotrectinib can cause central nervous system (CNS) adverse reactions including dizziness, ataxia, cognitive disorders, mood disorders, and sleep disorders. This may be considered in patients with neurological problems. Patients should be advised to contact their health care provider for new/worsening CNS symptoms.
Renal Dysfunction
Moderate:
Nubeqa
The darolutamide in Nubeqa has a moderate potential interaction with Renal Dysfunction.
Patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m2) who are not receiving hemodialysis have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose). No dose reduction is needed for patients with mild or moderate renal impairment. The effect of end stage renal disease (eGFR <15 mL/min/1.73 m2) on darolutamide pharmacokinetics is unknown.
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Renal Dysfunction.
The effect of severe renal dysfunction, kidney failure (estimated GFR less than 30 mL/min), or dialysis on repotrectinib pharmacokinetics is unknown. The recommended dosage of repotrectinib has not been established in patients with severe renal dysfunction or kidney failure or in patients on dialysis.
Report options
More resources
Nubeqa
A total of 341 drugs are known to interact with Nubeqa.
- Nubeqa is in the following drug classes: antiandrogens, hormones/antineoplastics.
- Nubeqa is used to treat Prostate Cancer.
repotrectinib
A total of 701 drugs are known to interact with repotrectinib.
- Repotrectinib is in the drug class multikinase inhibitors.
- Repotrectinib is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.